Lansoprazole associated with a relatively lower gout risk among PPI users: a nationwide retrospective study
Among PPI users, lansoprazole is associated with a significantly lower risk of gout. For patients at risk of gout who require PPI therapy, lansoprazole may be considered the treatment of choice.
Authors
- Ming‐Hsun Lin (ORCID: https://orcid.org/0000-0003-4169-921X)
- Yu-Te Su
- Hung-Kai Shih
- Tsung‐Kun Lin (ORCID: https://orcid.org/0000-0001-9421-7371)
- Wen‐Tung Wu (ORCID: https://orcid.org/0000-0001-9217-3352)
- Sy‐Jou Chen (ORCID: https://orcid.org/0000-0002-2105-7570)
- Chen‐Chih Chu (ORCID: https://orcid.org/0000-0002-1599-0305)
- Chiu‐Ching Huang (ORCID: https://orcid.org/0000-0003-3545-9770)
- Yu‐Ching Chou
Institutions
- Tri-Service General Hospital (TW)
- Tri-Service General Hospital Songshan Branch (TW)
- National Defense Medical Center (TW)
Publication Details
- Journal
- Clinical Rheumatology
- Published
- 2025-06-03
- DOI
- https://doi.org/10.1007/s10067-025-07502-z
- Citations
- 1
- Primary Topic
- Gout, Hyperuricemia, Uric Acid
- Type
- article
- Field-Weighted Citation Impact
- 1.43
Funders
- Tri-Service General Hospital